⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1541232 | 0.94 | — | — | |
| SCHEMBL1541932 | 0.92 | ALDH1A1 (0.30) | — | |
| SCHEMBL16704320 | 0.92 | ALDH1A1 (0.30) | — | |
| SCHEMBL1541935 | 0.92 | ALDH1A1 (0.30) | — | |
| SCHEMBL1541022 | 0.92 | ALDH1A1 (0.30) | — | |
| SCHEMBL16168100 | 0.73 | — | — | |
| SCHEMBL3380327 | 0.72 | TRIM24 (0.35) | — | |
| SCHEMBL9063237 | 0.69 | TRIM24 (0.39) | — | |
| SCHEMBL9063242 | 0.69 | TRIM24 (0.39) | — | |
| SCHEMBL9063244 | 0.69 | TRIM24 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040408-A | Colorimetric-near infrared dual-detection fluorescent probe for hypochlorous acid detection and preparation method and application thereof | 镇江江南化工有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260092073-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-02 | — | — | US | disclosed |
| CN-120040408-A | Colorimetric-near infrared dual-detection fluorescent probe for hypochlorous acid detection and preparation method and application thereof | 镇江江南化工有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2024218100-A1 | OXAZOLO[4,5-B]PYRAZINE AND OXAZOLO[4,5-B]PYRIDINE DERIVATIVES AS NLRP3 INHIBITORS FOR THE TREATMENT OF E.G. INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-24 | — | — | WO | disclosed |
| US-11945830-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4298103-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-117043166-A | Antiviral heterocyclic compounds | 英安塔制药有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023200441-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230265065-A1 | SELECTIVE PHOSPHATASE INHIBITORS BASED ON ILLUDALIC ACID | THE WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY | 2023-08-24 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| US-5986131-A | UNSATURATED CARBOXYLIC ACID DERIVATIVES AS LIGANDS AND RETINOIC ACID RECEPTORS | HOFFMANN-LA ROCHE INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0728742-B1 | Novel retinoids | HOFFMANN LA ROCHE (CH) | 1999-10-20 | — | — | EP | disclosed |
| EP-0775103-B1 | RETINOIC ACID X-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 1999-06-09 | — | — | EP | disclosed |
| US-5801253-A | Retinoic acid X-receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0775103-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-28 | — | — | EP | disclosed |
| EP-0728742-A2 | Novel retinoids | F. HOFFMANN-LA ROCHE AG (CH) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996005165-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-02-22 | — | — | WO | disclosed |